<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93896">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01657955</url>
  </required_header>
  <id_info>
    <org_study_id>RGN0117</org_study_id>
    <nct_id>NCT01657955</nct_id>
  </id_info>
  <brief_title>Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
  <acronym>CLL</acronym>
  <official_title>Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Lanjin Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Lanjin Pharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bendamustine is effective in the treatment
      of initial treatment of  Chronic Lymphocytic Leukemia (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival(PFS)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Leukemia</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Bendamustine Hydrochloride Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorambucil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC＜4×109 /L at d12-d14 );</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride Injection</intervention_name>
    <arm_group_label>Bendamustine Hydrochloride Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <arm_group_label>Chlorambucil</arm_group_label>
    <other_name>Leukeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of CLL;

          -  No prior or no standard treatment for CLL;

          -  Binet stage B, C or symptomatic stage A;

          -  Needs treatment to control diseases;

          -  (Eastern Cooperative Oncology Group)ECOG performance status ≤ 2

          -  Life expectancy ≥3 months

          -  Written informed consent

        Exclusion Criteria:

          -  Patients were diagnosed with or treated for malignant tumors other than CLL
             (including active central nervous system lymphoma) within one year prior to entering
             the study

          -  Transformation to Richter's syndrome, or prolymphocytic leukemia(PLL)

          -  Autoimmune hemolytic anemia requiring glucocorticoid therapy

          -  Autoimmune thrombocytopenia requiring glucocorticoid therapy

          -  Alanine aminotransferase(ALT)＞3 times upper limits of normal value, Aspartate
             aminotransferase(AST)＞3 times upper limits of normal value, Total bilirubin(TBIL)＞2
             times upper limits of normal value, serum creatinine＞1.5 times upper limits of normal
             value;

          -  Other serious Concomitant diseases which affect participation of this
             study(uncontrolled diabetes, gastric ulcer, cardiac and pulmonary diseases, at active
             phases of autoimmune diseases;

          -  Serious or uncontrolled infections;

          -  Central nervous system dysfunction with clinical symptoms;

          -  Patients received major surgery within 30 days prior to study entry;

          -  Pregnant or lactating women

          -  Allergic to study drug or mannitol

          -  Participation in any other clinical trials within 3 months prior to study   entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu G Qiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematologic Hospital of Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu G Qiu, M.D.</last_name>
    <phone>+86-02223909172</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian J Yu, Master</last_name>
    <phone>+86-15336402751</phone>
    <email>yujj@lanjin.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematologic hospital of Chinese academy of medical sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu G Qiu, M.D.</last_name>
      <phone_ext>+8602223909172</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Jian J Yu, Master</last_name>
      <phone>+8615336402752</phone>
      <email>yujj@lanjin.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Lu G Qiu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://lanjin.cn</url>
  </link>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 3, 2012</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Bendamustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
